medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability

Melchor-Mendoza YK, Martínez-Benítez B, Mina-Hawat A, Rodríguez-Leal G, Duque X, Moran-Villota S

Language: English
References: 30
Page: 430-435
PDF size: 147.46 Kb.


ABSTRACT

Introduction. There is little information on survival rates of patients with primary biliary cholangtis (PBC) in developing countries. This is particularly true in Latin America, where the number of liver transplants performed remains extremely low for patients with advanced liver disease who fulfill criteria for liver transplantation. The goal of this study was to compare survival rate of patients with PBC in developing countries who were treated with ursodeoxycholic acid (UDCA) versus survival of patients who received other treatments (OT) without UDCA, prescribed before the UDCA era. Material and methods. A retrospective study was performed, including records of 78 patients with PBC in the liver unit in a third level referral hospital in Mexico City. Patients were followed for five years from initial diagnosis until death related to liver disease or to the end of the study. Patients received UDCA (15 mg/kg/per day) (n = 41) or OT (n = 37) before introduction of UDCA in Mexico. Results. Response to treatment was higher in the group that received UDCA. In the five years of follow-up, survival rates were significantly higher in the UDCA group than in the OT group. The hazard ratio of death was higher in the OT group vs. UDCA group, HR 8.78 (95% CI, 2.52-30.61); Mayo Risk Score and gender were independently associated with the risk of death. Conclusions. The study confirms that the use of UDCA in countries with a limited liver transplant program increases survival in comparison to other treatments used before the introduction of UDCA.


REFERENCES

  1. Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis 2013; 17: 229-42.

  2. Zhang LN, Shi TY, Shi XH, Wang L, Yang YJ, Liu B, Gao LX, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013; 58: 264-72.

  3. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.

  4. Corpechot C. Primary biliary cirrhosis beyond ursodeoxycholic acid. Semin Liver Dis 2016; 36: 15-26.

  5. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.

  6. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, et al., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.

  7. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gludd C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;Dec 12:CD000551. DOI: 10.1002/ 14651858.CD000551.pub3.

  8. Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005; 21: 217-26.

  9. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-12.

  10. Kratz A, Feraro M, Sluss PM, Lewandrowski KB. Laboratory reference values. N Engl J Med 2004; 351: 1548-63.

  11. Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55: 1361-7.

  12. Kuiper EMM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJM, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.

  13. Hosmer D, Lemechow S, Susanne M. Applied Survival Analysis. Regression Modeling of Time-to-Event data. Second Edition. John Wiley & Sons, Inc. Hoboken; New Jersey. USA: 2008.

  14. Morán S, Rodríguez-Leal G, Marín-López E, Arista J, Poo JL, Vargas-Vorackova F, Kershenobich D, et al. Cirrosis biliar primaria: características clínicas y supervivencia en la población mexicana. Rev Gastroenterol Mex 1996; 61: 212-19.

  15. Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, Cazzagon N, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 2011; 31: 361-8.

  16. Poupon RE, Bonnand AM, Chrétien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 1999; 29: 1668-71.

  17. Papastergiou V, Tsochatzis EA, Rodriguez-Peralvarez M, Thalassinos E, Pieri G, Manousou P, Germani G, et al. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther 2013; 38: 1354-64.

  18. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-50.

  19. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.

  20. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, et al. A randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-66.

  21. Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-54.

  22. Heathcote EJ1, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.

  23. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.

  24. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42: 1194-202.

  25. Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, Zhang FC. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol 2013; 19: 1111-18.

  26. Azemoto N, Kumagi T, Abe M, Konishi I, Matsuura B, Hiasa Y, Onji M. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011; 41: 310-17.

  27. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.

  28. Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14: 3313-27.

  29. Garcia VD, Garcia CD, Santiago-Delpin EA. Organ transplants in Latin America. Transplant Proc 2003; 35: 1673-74.

  30. Hepp J, Innocenti FA. Liver transplantation in Latin America: current status. Transplant Proc 2004; 36: 1667-8.




2020     |     www.medigraphic.com